Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 21097713)

1.

Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.

Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, Huh SJ, Amin S, Meyers C, Robertson GP.

Cancer Prev Res (Phila). 2011 Feb;4(2):248-58. doi: 10.1158/1940-6207.CAPR-10-0106. Epub 2010 Nov 19.

2.

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP.

Clin Cancer Res. 2009 Mar 1;15(5):1674-85. doi: 10.1158/1078-0432.CCR-08-2214. Epub 2009 Feb 10.

3.

Melanoma prevention using topical PBISe.

Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Cancer Prev Res (Phila). 2011 Jun;4(6):935-48. doi: 10.1158/1940-6207.CAPR-10-0202. Epub 2011 Mar 2.

4.

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP.

Cancer Res. 2008 Sep 15;68(18):7638-49. doi: 10.1158/0008-5472.CAN-07-6614.

5.

PRAS40 deregulates apoptosis in malignant melanoma.

Madhunapantula SV, Sharma A, Robertson GP.

Cancer Res. 2007 Apr 15;67(8):3626-36.

6.

Deregulated Akt3 activity promotes development of malignant melanoma.

Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP.

Cancer Res. 2004 Oct 1;64(19):7002-10.

7.

Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.

Vogt T, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, Landthaler M, McClelland M.

Clin Cancer Res. 1998 Mar;4(3):791-7.

8.

Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.

Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM, Kuphal S.

Mol Carcinog. 2014 Aug;53(8):635-47. doi: 10.1002/mc.22018. Epub 2013 Apr 26.

PMID:
23625515
9.

Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Mol Cancer Ther. 2013 Jan;12(1):3-15. doi: 10.1158/1535-7163.MCT-12-0492. Epub 2012 Oct 30.

10.

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS.

PLoS One. 2013;8(3):e59380. doi: 10.1371/journal.pone.0059380. Epub 2013 Mar 12. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aaa12360-0c90-42c3-bc43-d00022b68b81.

11.

Targeting sphingosine kinase-1 to inhibit melanoma.

Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP.

Pigment Cell Melanoma Res. 2012 Mar;25(2):259-74. doi: 10.1111/j.1755-148X.2012.00970.x.

12.

Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: thiol reactivity and its implications.

Crampsie MA, Pandey MK, Desai D, Spallholz J, Amin S, Sharma AK.

Chem Biol Interact. 2012 Oct 25;200(1):28-37. doi: 10.1016/j.cbi.2012.08.022. Epub 2012 Sep 13.

13.

Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.

Berthier-Vergnes O, Kharbili ME, de la Fouchardière A, Pointecouteau T, Verrando P, Wierinckx A, Lachuer J, Le Naour F, Lamartine J.

Br J Cancer. 2011 Jan 4;104(1):155-65. doi: 10.1038/sj.bjc.6605994. Epub 2010 Nov 16.

14.

Functional effects of GRM1 suppression in human melanoma cells.

Wangari-Talbot J, Wall BA, Goydos JS, Chen S.

Mol Cancer Res. 2012 Nov;10(11):1440-50. doi: 10.1158/1541-7786.MCR-12-0158. Epub 2012 Jul 13.

15.

Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

El Khoury D, Destouches D, Lengagne R, Krust B, Hamma-Kourbali Y, Garcette M, Niro S, Kato M, Briand JP, Courty J, Hovanessian AG, Prévost-Blondel A.

BMC Cancer. 2010 Jun 24;10:325. doi: 10.1186/1471-2407-10-325.

16.

Selenium-containing histone deacetylase inhibitors for melanoma management.

Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Cancer Biol Ther. 2012 Jul;13(9):756-65. Epub 2012 Jun 6.

17.

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP.

Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.

18.

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.

Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20.

19.

p54nrb is a new regulator of progression of malignant melanoma.

Schiffner S, Zimara N, Schmid R, Bosserhoff AK.

Carcinogenesis. 2011 Aug;32(8):1176-82. doi: 10.1093/carcin/bgr103. Epub 2011 Jun 3.

20.

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.

Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lötsch D, Heffeter P, Hegedus B, Grusch M, Kiss R, Berger W.

Oncotarget. 2012 Apr;3(4):399-413.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk